Detalhe da pesquisa
1.
Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1-98 clinical trial.
Cancer
; 127(5): 700-708, 2021 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33290610
2.
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
N Engl J Med
; 379(2): 122-137, 2018 Jul 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29863451
3.
Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial.
Breast Cancer Res Treat
; 185(3): 697-707, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33159633
4.
Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial.
Br J Cancer
; 122(7): 1119, 2020 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-31949268
5.
Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy.
Breast Cancer Res Treat
; 181(2): 347-359, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32274665
6.
Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence.
Breast Cancer Res
; 21(1): 153, 2019 12 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-31888717
7.
Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial.
Br J Cancer
; 120(10): 959-967, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30967649
8.
Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial.
Lancet Oncol
; 19(10): 1385-1393, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30196031
9.
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 19(1): 127-138, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29158011
10.
Adjuvant ovarian suppression in premenopausal breast cancer.
N Engl J Med
; 372(5): 436-46, 2015 Jan 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-25495490
11.
Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00.
Breast Cancer Res Treat
; 170(2): 351-360, 2018 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-29589138
12.
When do patient reported quality of life indicators become prognostic in breast cancer?
Health Qual Life Outcomes
; 16(1): 13, 2018 Jan 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29329582
13.
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.
N Engl J Med
; 371(2): 107-18, 2014 Jul 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-24881463
14.
Poor Prognosis After Second Locoregional Recurrences in the CALOR Trial.
Ann Surg Oncol
; 24(2): 398-406, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-27663567
15.
Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial.
Breast Cancer Res
; 18(1): 110, 2016 11 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27825388
16.
Adjuvant ovarian function suppression and cognitive function in women with breast cancer.
Br J Cancer
; 114(9): 956-64, 2016 04 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-27092785
17.
Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.
Lancet Oncol
; 16(7): 848-58, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-26092816
18.
ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer.
Breast Cancer Res Treat
; 154(3): 543-55, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26590813
19.
Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials.
Breast Cancer Res Treat
; 154(2): 275-86, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26493064
20.
CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.
Breast Cancer Res Treat
; 151(2): 373-84, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25935582